Zacks: Innophos Holdings, Inc. (IPHS) Given Consensus Rating of “Buy” by Brokerages

Innophos Holdings, Inc. (NASDAQ:IPHS) has earned a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Innophos’ rating score has improved by 33.3% in the last three months as a result of a number of analysts’ ratings changes.

Brokerages have set a 1-year consensus price objective of $51.00 for the company and are expecting that the company will post $0.43 EPS for the current quarter, according to Zacks. Zacks has also assigned Innophos an industry rank of 190 out of 255 based on the ratings given to its competitors.

Several equities analysts recently weighed in on IPHS shares. Zacks Investment Research upgraded shares of Innophos from a “strong sell” rating to a “hold” rating in a research report on Friday, January 4th. BidaskClub upgraded shares of Innophos from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 15th. ValuEngine upgraded shares of Innophos from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. Seaport Global Securities assumed coverage on shares of Innophos in a research report on Thursday, February 21st. They set a “buy” rating for the company. Finally, TheStreet upgraded shares of Innophos from a “c” rating to a “b-” rating in a research report on Thursday, February 21st.



Large investors have recently modified their holdings of the business. Penn Capital Management Co. Inc. lifted its holdings in shares of Innophos by 6.5% in the third quarter. Penn Capital Management Co. Inc. now owns 84,083 shares of the specialty chemicals company’s stock worth $3,733,000 after buying an additional 5,160 shares in the last quarter. Vanguard Group Inc lifted its holdings in shares of Innophos by 2.0% in the third quarter. Vanguard Group Inc now owns 2,065,439 shares of the specialty chemicals company’s stock worth $91,705,000 after buying an additional 41,101 shares in the last quarter. Confluence Investment Management LLC lifted its holdings in shares of Innophos by 6.4% in the fourth quarter. Confluence Investment Management LLC now owns 119,672 shares of the specialty chemicals company’s stock worth $2,935,000 after buying an additional 7,248 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Innophos by 31.5% in the third quarter. Morgan Stanley now owns 101,185 shares of the specialty chemicals company’s stock worth $4,493,000 after buying an additional 24,241 shares in the last quarter. Finally, Investment Counselors of Maryland LLC lifted its holdings in shares of Innophos by 1.9% in the fourth quarter. Investment Counselors of Maryland LLC now owns 494,138 shares of the specialty chemicals company’s stock worth $12,121,000 after buying an additional 9,217 shares in the last quarter. Hedge funds and other institutional investors own 93.45% of the company’s stock.

IPHS traded down $0.46 during trading on Wednesday, hitting $32.15. 53,700 shares of the company traded hands, compared to its average volume of 117,008. The firm has a market cap of $636.15 million, a P/E ratio of 14.10 and a beta of 1.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.13 and a current ratio of 2.52. Innophos has a one year low of $22.57 and a one year high of $50.40.

Innophos (NASDAQ:IPHS) last posted its quarterly earnings results on Wednesday, February 20th. The specialty chemicals company reported $0.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.03. The company had revenue of $192.74 million during the quarter, compared to analyst estimates of $189.60 million. Innophos had a net margin of 4.50% and a return on equity of 13.39%. The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.52 earnings per share. Equities research analysts predict that Innophos will post 2.23 earnings per share for the current fiscal year.

Innophos Company Profile

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

Further Reading: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.